Vertex Pharma (VRTX) Receives EC Approval of KALYDECO in Certain Patients with CF
Tweet Send to a Friend
Vertex Pharma (Nasdaq: VRTX) announced that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE